Tapping the Potential of Atrial Fibrillation Devices
This article was originally published in Start Up
A solid foundation has been laid in the field of devices for atrial fibrillation; clinical trials have underscored the efficacy of cardiac ablation devices compared to drugs, reimbursement is in place for both surgical and catheter-based ablation procedures, and large companies have invested heavily in the technologies, validating the entire field. Early devices on the market are bringing in some revenues for their developers, but much remains to be done before atrial fibrillation becomes the multi-billion market everyone talks about. The biggest challenge that lies ahead: clinical trials, for today, all ablation devices are used off-label for atrial fibrillation.
You may also be interested in...
Despite widespread and increasing prevalence, atrial fibrillation has frustrated clinicians, device companies, and investors, resulting in only a small number of doctors treating a small number of patients. Ablation Frontiers believes its system will finally enable many more doctors to treat all types of AF patients because it is developing products and procedures that are simpler for doctors to use and perform, finally providing a broad-based solution to this rapidly growing market.
The first chapter of natural orifice surgery begins with the Apollo Group, a group of world-renowned gastroenterologists and surgeons who were frustrated with the pace of innovation in gastroenterology. They believed that there ought to be a better way to take advantage of the natural orifice access and the flexible endoscopy platforms with which they were familiar, to do more interventional procedures. The efforts of the group resulted in a pooled set of intellectual property, which became the basis of start-up Apollo Endosurgery. Apollo aims to provide surgical instrumentation designed specifically for NOTES, to help the field learn just how far minimally invasive surgery can go.
While no medical device start-up operates in a risk-free zone, CyberHeart is minimizing its risk by using core technology that is already proven in another therapeutic area, cancer. The start-up has licensed cardiac tissue ablation rights to Accuray Inc.'s CyberKnife robotic radiosurgery system, and intends to use it to develop a completely noninvasive approach for the large, unmet atrial fibrillation market.